CA3235310A1 - Neutralizing monoclonal antibodies against sarbecoviruses - Google Patents

Neutralizing monoclonal antibodies against sarbecoviruses Download PDF

Info

Publication number
CA3235310A1
CA3235310A1 CA3235310A CA3235310A CA3235310A1 CA 3235310 A1 CA3235310 A1 CA 3235310A1 CA 3235310 A CA3235310 A CA 3235310A CA 3235310 A CA3235310 A CA 3235310A CA 3235310 A1 CA3235310 A1 CA 3235310A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
chain variable
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3235310A
Other languages
English (en)
French (fr)
Inventor
Nicasio MANCINI
Nicola CLEMENTI
Massimo Clementi
Elena CRISCUOLO
Sofia SISTI
Martina LIBERA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IRCCS Ospedale San Raffaele
Original Assignee
IRCCS Ospedale San Raffaele
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IRCCS Ospedale San Raffaele filed Critical IRCCS Ospedale San Raffaele
Publication of CA3235310A1 publication Critical patent/CA3235310A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3235310A 2021-10-29 2022-07-20 Neutralizing monoclonal antibodies against sarbecoviruses Pending CA3235310A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21205626.1 2021-10-29
EP21205626.1A EP4174083A1 (en) 2021-10-29 2021-10-29 Neutralizing monoclonal antibodies against sarbecoviruses
PCT/IB2022/056706 WO2023073441A1 (en) 2021-10-29 2022-07-20 Neutralizing monoclonal antibodies against sarbecoviruses

Publications (1)

Publication Number Publication Date
CA3235310A1 true CA3235310A1 (en) 2023-05-04

Family

ID=78414544

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3235310A Pending CA3235310A1 (en) 2021-10-29 2022-07-20 Neutralizing monoclonal antibodies against sarbecoviruses

Country Status (7)

Country Link
US (1) US20260234220A1 (cg-RX-API-DMAC7.html)
EP (2) EP4174083A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024540147A (cg-RX-API-DMAC7.html)
AU (1) AU2022374853A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235310A1 (cg-RX-API-DMAC7.html)
IL (1) IL312392A (cg-RX-API-DMAC7.html)
WO (1) WO2023073441A1 (cg-RX-API-DMAC7.html)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE062777T2 (hu) * 2020-02-26 2023-12-28 Vir Biotechnology Inc SARS-CoV-2 elleni antitestek
US20230348571A1 (en) * 2020-04-06 2023-11-02 Vanderbilt University Cross-reactive coronavirus antibodies and uses thereof

Also Published As

Publication number Publication date
JP2024540147A (ja) 2024-10-31
IL312392A (en) 2024-06-01
WO2023073441A1 (en) 2023-05-04
EP4174083A1 (en) 2023-05-03
EP4423124A1 (en) 2024-09-04
AU2022374853A1 (en) 2024-05-16
US20260234220A1 (en) 2026-08-13

Similar Documents

Publication Publication Date Title
AU2013229488B2 (en) Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof
CA2703667A1 (en) Anti-rsv g protein antibodies
WO2021207152A1 (en) Cross-reactive coronavirus antibodies and uses thereof
US20240182549A1 (en) Peptides and antibody fusions that bind to sars-cov-2 and methods of using same
JP2013505236A (ja) Hiv−1抗体
WO2025246679A1 (zh) 一种广谱中和冠状病毒的抗体及其应用
WO2021105669A1 (en) Antibodies
CN103224559B (zh) 人源hiv广谱中和抗体a16及其相关生物材料与应用
Pavan et al. Nanobodies against SARS-CoV-2 reduced virus load in the brain of challenged mice and neutralized Wuhan, Delta and Omicron Variants
EP4423124A1 (en) Neutralizing monoclonal antibodies against sarbecoviruses
EP4687973A1 (en) Combined antibodies against sarbecoviruses and uses thereof
CN116675766A (zh) 人源化高中和活性抗新型冠状病毒单克隆抗体及应用
Li et al. N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies
CN107383190A (zh) 人源抗HIVgp41特异性抗体及其应用
TW202346329A (zh) 冠狀病毒之特異性抗體及其用途
CN121335920A (zh) 靶向HIV Env上的CD4结合位点的广谱中和抗体
CA2509387A1 (en) Peptide oligomers for use as hiv vaccines
IL278955A (en) Antibodies against sars cov-2
CN102212133B (zh) 人源HIV抗体的Fab片段及其编码基因与应用
CN119371521A (zh) 一种广谱抗新型冠状病毒SARS-CoV-2的纳米抗体及其应用
HK1200176B (en) Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
NZ729856B2 (en) Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof

Legal Events

Date Code Title Description
P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P145 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - DEFECT(S)

Effective date: 20240923

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241105

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250121

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250711

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250711

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20251204